Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food ...

To evaluate the influence of environmental factors and prematurity relating to juvenile dermatomyositis (JDM), its course and refractoriness to treatment. Maternal exposure to occupational pollutants ...

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical ...

Discover how pain interference impacts children with juvenile idiopathic arthritis. Learn about the key factors influencing ...

Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...

Additional data across broad patient types and disease manifestations (domains) will highlight the benefits of treatment with TREMFYA ® for moderate to severe plaque psoriasis (PsO) and active PsA.

Nov. 8, 2024 — Changes in the gut microbiome before rheumatoid arthritis is developed could provide a window of opportunity for preventative treatments, new research ... Two Key Genes Identified ...

Though it’s the most common skin condition in the United States, determining the best acne treatment for your skin is still challenging. Acne treatments include prescription medications ...

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.

New insights on genetic variants and phenotypic features of childhood large-vessel vasculopathy: a systematic review and single-centre series. Six medico-psycho-social dimensions of a pedagogical ...